I

InflaRx NV
D

IFRX

1.85000
USD
0.00
(0.11%)
مغلق
حجم التداول
7,204
الربح لكل سهم
-1
العائد الربحي
-
P/E
-2
حجم السوق
124,196,553
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    ALNY
    ALNY
    -0.480
    (-0.19%)
    250.450 USD
    B
    BMRN
    -0.525
    (-0.76%)
    68.215 USD
    C
    CRSP
    -2.620
    (-5.19%)
    47.840 USD
    E
    EDIT
    -0.14000
    (-6.80%)
    1.92000 USD
    N
    NTLA
    -0.075
    (-0.61%)
    12.180 USD
    Q
    QURE
    -0.130
    (-1.00%)
    12.840 USD
    REGN
    REGN
    4.37
    (0.63%)
    700.66 USD
    S
    SGMO
    -0.04500
    (-4.00%)
    1.08000 USD
    VRTX
    VRTX
    4.10
    (0.85%)
    484.53 USD
    المزيد
الأخبار
المقالات

العنوان: InflaRx NV

القطاع: Healthcare
الصناعة: Biotechnology
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.